Pinatuzumab 是一种靶向细胞表面抗原 CD22 的人源化单克隆抗体。Pinatuzumab 可用于合成抗体-药物偶联物，例如 Pinatuzumab vedotin。Pinatuzumab 可用于研究非霍奇金淋巴瘤等癌症。Pinatuzumab 的同型对照可参考 Human IgG1 kappa, Isotype Control。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab) is 97.02%, determined by SEC-HPLC.

Immobilized human CD22 His at 2 ug/mL can bind Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab), EC50=0.008601 ug/mL.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.